Notch signalling in primary cutaneous CD30+ lymphoproliferative disorders: a new therapeutic approach?

Br J Dermatol. 2010 Oct;163(4):781-8. doi: 10.1111/j.1365-2133.2010.09915.x. Epub 2010 Sep 2.

Abstract

Background: The oncogenic potential of deregulated Notch signalling has been described in several haematopoietic malignancies. We have previously reported an increased expression of Notch1 in primary cutaneous CD30+ lymphoproliferative disorders, lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma (pcALCL).

Objectives: To investigate the functional importance of Notch signalling in cell lines derived from pcALCL.

Methods: Cell lines derived from pcALCL (Mac1, Mac2a and JK) were treated with different γ-secretase inhibitors (GSIs) (GSI I, IX, XX and XXI). The effects of GSIs on cell viability, apoptosis and cell cycle progression were measured as well as the impact of GSI I on the known prosurvival pathway Akt-mTOR-FOXO3a.

Results: Notch family members were expressed in all investigated pcALCL cell lines. GSI I had a marked proapoptotic effect, but GSI IX, XX and XXI were much less potent. The GSI I-triggered apoptosis was preceded by an accumulation of cells in the G2/M, cyclin B1-controlled phase of the cell cycle accompanied by an increase in the cyclin-dependent kinase inhibitor, p21(WAF/Cip) . GSI I induced the nuclear translocation of proapoptotic FOXO3a, probably via an Akt-independent pathway.

Conclusions: Notch signalling may be a future therapeutic target for the treatment of advanced pcALCL.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid Precursor Protein Secretases / antagonists & inhibitors
  • Antineoplastic Agents / pharmacology
  • Apoptosis / drug effects
  • Cell Cycle / drug effects
  • Cell Survival / drug effects
  • Dose-Response Relationship, Drug
  • Drug Screening Assays, Antitumor / methods
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Ki-1 Antigen / analysis
  • Lymphoma, Large-Cell, Anaplastic / metabolism*
  • Lymphoma, Large-Cell, Anaplastic / pathology
  • Neoplasm Proteins / antagonists & inhibitors
  • Neoplasm Proteins / metabolism
  • Oligopeptides / pharmacology
  • Receptors, Notch / antagonists & inhibitors
  • Receptors, Notch / metabolism*
  • Signal Transduction / drug effects
  • Skin Neoplasms / metabolism*
  • Skin Neoplasms / pathology
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Ki-1 Antigen
  • Neoplasm Proteins
  • Oligopeptides
  • Receptors, Notch
  • benzyloxycarbonyl-leucyl-leucyl-norleucinal
  • Amyloid Precursor Protein Secretases